Being diagnosed with Type 2 diabetes is a life-changing event. For the rest of your life, you will need to watch what you eat and monitor your glucose levels. Your doctor will prescribe medication that will help you with your disease. But what if that drug can cause more harm than good?
That may be the case for those who have taken Onglyza. And we’re here to help.
For almost 20 years, the personal injury lawyers at Fellerman & Ciarimboli have been fighting for the rights of the injured throughout the state of Pennsylvania. We understand the pain and anger that you must feel. That’s why we’re ready to fight for your rights both inside and outside the courtroom to make sure you get compensated for your injuries.
The Deadly Risk of Onglyza
Onglyza (saxagliptin) is used to treat and manage Type 2 diabetes. The drug, manufactured by AstraZeneca, regulates the levels of insulin in your body after you have a meal and is used as part of a treatment program that includes diet, exercise, and possibly other medications.
Since Type 2 diabetes patients have an increased risk of cardiovascular complications, the U.S. Food and Drug Administration had recommended to new Type 2 diabetes drug makers in 2008 to provide evidence that their drugs do not increase cardiovascular events such as heart attacks or failure.
Although Onglyza met the FDA’s safety criteria, a post-marketing study had found out of 16,000 randomly chosen patients, 27 percent of patients taking the medication were more likely to be hospitalized for heart failure. The SAVOR study had also found there was a significant increase in “all-cause mortality” rate among Onglyza. In addition to an increased risk of heart failure, Onglyza could lead to severe joint pain, pancreatic cancer, and thyroid cancer.